For the very first time, we are uniting leading pharma, pioneering biotechs and reputed academics at the Wnt & β-Catenin Targeted Drug Discovery Summit this November to share lessons learned to regulate this pathway and exploit untapped therapeutic potentials – bringing novel treatments for patients from oncology to autoimmune to regenerative medicine.
Bringing together world leaders and thought pioneers in the Wnt pathway, the Wnt & β-Catenin Targeted Drug Discovery Summit will be the only virtual event to unite 80+ industry drug developers and academic KOLs to provide you exclusive insights and real world data you cannot find elsewhere.
Conference Pass - Drug Developer USD 2099.00
Conference Pass - Solution Provider USD 2599.00
Conference Pass - Academic USD 1899.00
Speakers: Brent A. Hanks Associate Professor of Medical Oncology Duke University, Duke Cancer Institute, David Carbone Professor of Medicine The Ohio State University, Ken M. Cadigan Professor of Molecular, Cellular & Developmental Biology University of Michigan, Melanie Koenigshoff Head of Lung Repair & Regeneration Helmholtz Zentrum München, Trever Bivona Professor - Hematology & Oncology University of California San Francisco, Weilin Xie Professor Shandong First Medical University, Donald J Buchsbaum Senior Advisor for Cancer Immunology, O’Neal Comprehensive Cancer Center University of Alabama of Birmingham, Elmar Nurmemmedov Principal Investigator & Director of Drug Discovery Saint John’s Cancer Institute, Maneesh Kumar Research Director, Coordinating Center Desmoid Tumor Research Foundation, Marc Van Wetering Senior Researcher, Clevers Group Prinses Máxima Centrum, Marek Mlodzik Chair of the Department of Molecular, Cell & Developmental Biology Mount Sinai School of Medicine, Regan Memmot Assistant Professor in Medical Oncology The Ohio State University, Gary A. Piazza Department Head, Drug Discovery & Development Auburn University, Rami N. Hannoush Senior Principal Scientist and Group Leader, Early Discovery Biochemistry Genentech, Rebecca Arend Associate Professor University of Alabama of Birmingham, Somasekar Seshagiri Chief Executive Officer & Chief Scientific Officer AntlerA Therapeutics, Stephen Horrigan Chief Scientific Officer Iterion Therapeutics, Trudy Vanhove Chief Medical Officer Surrozen, Aris Persidis President Biovista, Caroline Phillips Head of Oncology Redx Pharma, Greg Verdine Chairman, President & CEO Fog Pharma, Mike Kagey Senior Director of Translational Medicine Leap Therapeutics, Rahul Aras President & CEO Iterion Therapeutics, Simon Leedham Professor of Molecular & Population Genetics University of Oxford
Time: On Wednesday November 17, 2021 at 8:00 am (ends Thursday November 18, 2021 at 4:30 pm)